XML 39 R28.htm IDEA: XBRL DOCUMENT v3.23.1
Fair Value Measurements (Tables)
3 Months Ended
Mar. 31, 2023
Fair Value Disclosures [Abstract]  
Financial Assets and Liabilities Measured at Fair Value on Recurring Basis

The following table presents information about our financial assets and liabilities that are measured at fair value on a recurring basis and indicates the fair value hierarchy of the valuation:

 

 

 

March 31, 2023

 

 

 

Total

 

 

Level 1

 

 

Level 2

 

 

Level 3

 

 

 

(in thousands)

 

Assets

 

 

 

 

 

 

 

 

 

 

 

 

Cash equivalents:

 

 

 

 

 

 

 

 

 

 

 

 

Money market funds

 

$

52,144

 

 

$

52,144

 

 

$

 

 

$

 

Commercial paper

 

 

20,967

 

 

 

 

 

 

20,967

 

 

 

 

Agency discount notes

 

 

323,086

 

 

 

 

 

 

323,086

 

 

 

 

Total cash equivalents

 

 

396,197

 

 

 

52,144

 

 

 

344,053

 

 

 

 

Marketable securities:

 

 

 

 

 

 

 

 

 

 

 

 

Commercial paper

 

 

34,122

 

 

 

 

 

 

34,122

 

 

 

 

Total marketable securities

 

 

34,122

 

 

 

 

 

 

34,122

 

 

 

 

Investment in equity securities

 

 

49,803

 

 

 

49,803

 

 

 

 

 

 

 

LianBio Warrant

 

 

681

 

 

 

681

 

 

 

 

 

 

 

Total financial assets

 

$

480,803

 

 

$

102,628

 

 

$

378,175

 

 

$

 

Liabilities

 

 

 

 

 

 

 

 

 

 

 

 

Embedded derivative

 

$

1,231

 

 

$

 

 

$

 

 

$

1,231

 

Short-term liability

 

 

5,490

 

 

 

5,490

 

 

 

 

 

 

 

Total financial liabilities

 

$

6,721

 

 

$

5,490

 

 

$

 

 

$

1,231

 

 

 

 

December 31, 2022

 

 

 

Total

 

 

Level 1

 

 

Level 2

 

 

Level 3

 

 

 

(in thousands)

 

Assets

 

 

 

 

 

 

 

 

 

 

 

 

Cash equivalents:

 

 

 

 

 

 

 

 

 

 

 

 

Money market funds

 

$

202,250

 

 

$

202,250

 

 

$

 

 

$

 

Commercial paper

 

 

159,758

 

 

 

 

 

 

159,758

 

 

 

 

Total cash equivalents

 

 

362,008

 

 

 

202,250

 

 

 

159,758

 

 

 

 

Marketable securities:

 

 

 

 

 

 

 

 

 

 

 

 

Commercial Paper

 

 

51,580

 

 

 

 

 

 

51,580

 

 

 

 

Total marketable securities

 

 

51,580

 

 

 

 

 

 

51,580

 

 

 

 

Investment in equity securities

 

 

43,653

 

 

 

43,653

 

 

 

 

 

 

 

LianBio Warrant

 

 

570

 

 

 

570

 

 

 

 

 

 

 

Total financial assets

 

$

457,811

 

 

$

246,473

 

 

$

211,338

 

 

$

 

Liability

 

 

 

 

 

 

 

 

 

 

 

 

Embedded derivative

 

$

1,201

 

 

$

 

 

$

 

 

$

1,201

 

 

Summary of Total Realized and Unrealized Gains and Losses Associated with Investment in Equity Securities

Total realized and unrealized gains and losses associated with investment in equity securities during the periods presented consisted of the following:

 

 

 

Three Months Ended March 31,

 

 

 

2023

 

 

2022

 

 

 

(in thousands)

 

Net realized gains (losses) recognized on investment
  in equity securities sold

 

$

7,158

 

 

$

(1,244

)

Net unrealized losses recognized on investment
  in equity securities held as of the end of the period

 

 

(6,194

)

 

 

(11,622

)

Total net gains (losses) included in “Other income
  expense, net”

 

$

964

 

 

$

(12,866

)